CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Soleno Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Soleno Therapeutics Inc
100 Marine Parkway, Suite 400
Phone: (302) 658-7581p:302 658-7581 REDWOOD CITY, CA  94065  United States Ticker: SLNOSLNO
Business Summary
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer AnishBhatnagar 57 4/1/2025 1/1/2006
Chief Financial Officer JenniferFulk 49 3/2/2026 3/2/2026
Vice President - Regulatory Affairs Patricia C.Hirano 58 1/1/2024 1/1/2019
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
SOLENO THERAPEUTICS UK LTD GARDEN COTTAGE BADGEMORE PARK HENLEY-ON-THAMES UK
SOLENO THERAPEUTICS EUROPE LIMITED SUITE 10151 26 UPPER PEMBROKE STREET Ireland
Essentialis, Inc. 7915 Corte Cardo Carlsbad CA United States

Business Names
Business Name
Essentialis, Inc.
SLNO
Soleno Therapeutics Europe Ltd.
Soleno Therapeutics U.K. Ltd.
Soleno Therapeutics UK Ltd.

General Information
Number of Employees: 182 (As of 12/31/2025)
Outstanding Shares: 52,120,147 (As of 4/29/2026)
Shareholders: 31
Stock Exchange: NASD
Federal Tax Id: 770523891
Fax Number: (302) 655-5049
Email Address: info@capnia.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 12, 2026